Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dysport Swallowing Effect in Cervical Dystonia
NCT01384214Phase 4Completed
- Sponsor
- Allergan
- Start
- Oct 2008
- Primary completion
- Jun 2009
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of botulinum toxin type A in cervical dystonia (CD), sponsored by Allergan. Primary endpoint: Oropharyngeal Swallow Efficiency at Week 2. Started Oct 2008; status: completed.
02
Drugs
botulinum toxin type A
03
Conditions
cervical dystonia (CD)
Beyond the preview
Go deeper on NCT01384214.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01384214.